Microtech begins human trials of implantable microsensor for Heart Failure management.
Read more
Avid Bioservices' acquisition by GHO and Ampersand progresses with Hart-Scott-Rodino waiting period expiration.
Read more
CEL-SCI announces $5 million public offering to fund Multikine development for Head and Neck Neoplasms.
Read more
FDA approves TEVIMBRA for first-line treatment of HER2-negative Gastric and Gastroesophageal Junction Cancers with chemotherapy.
Read more
EC approves amivantamab and lazertinib for first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
Read more
NRx Pharmaceuticals submits NDA for NRX-100 (IV Ketamine) to FDA for Suicidal Depression treatment.
Read more
CARsgen's Claudin18.2 CAR-T shows positive results in Phase II trial for Gastric Cancer in China.
Read more
Vor Bio secures $55.6M in private placement to advance trials for Acute Myeloid Leukemia therapies.
Read more
KALA BIO secures $10.75M in private placement to advance KPI-012 for Persistent Corneal Epithelial Defect.
Read more
Takeda's HYQVIA approved in Japan for Agammaglobulinemia and Hypogammaglobulinemia, offering less frequent dosing for patients.
Read more
Microbot Medical submits FDA 510(k) for LIBERTY® Endovascular Robotic System, aiming for 2025 U.S. commercial launch.
Read more
AusperBio secures $73M to advance Phase 2 trials for chronic Hepatitis B therapy AHB-137.
Read more
BeiGene secures global rights for Duality Biologics' B7H4 ADC, achieving a milestone in solid tumor therapy development.
Read more
IDEAYA licenses SHR-4849 ADC for Small Cell Lung Cancer and Neuroendocrine Tumors, targeting US IND filing in 2025.
Read more
Precigen submits BLA for PRGN-2012, seeking FDA priority review for Recurrent Respiratory Papillomatosis treatment.
Read more
Chimerix submits NDA for dordaviprone to FDA for recurrent H3 K27M-mutant diffuse glioma, seeking accelerated approval.
Read more
Citius Oncology receives FDA approval for LYMPHIR to treat Cutaneous T-Cell Lymphoma and reports increased financial losses for 2024.
Read more
Vincerx Pharma announces strategic merger with Oqory, focusing on ADCs for oncology indications.
Read more
Immedica to acquire Marinus Pharmaceuticals, enhancing rare disease portfolio with FDA-approved seizure treatment ZTALMY.
Read more
Radiopharm partners with Lantheus for Phase 1 trial of radiopharmaceuticals targeting solid tumors in Australia.
Read more
Novartis' Phase III trial shows efficacy of OAV101 IT in Spinal Muscular Atrophy patients.
Read more
Traws Pharma secures $72.6M funding to advance Tivoxavir Marboxil for H5N1 Bird Flu treatment.
Read more
ADC Therapeutics completes Phase 3 trial enrollment for ZYNLONTA in Diffuse Large B-Cell Lymphoma.
Read more
Huadong Medicine and SynerK partner to develop siRNA drug SNK-2726 for Hypertension treatment in Greater China.
Read more
Axsome's AXS-05 shows efficacy in Phase 3 trials for Alzheimer's Disease agitation, with NDA submission planned for 2025.
Read more
